Sixty-nine ( @ % ) of @ patients receiving pegloticase developed high titer anti-pegloticase Ab ( > @:@ ) and @ % ( @/@ ) developed anti-PEG Ab ; @ patient receiving placebo developed high titer anti-pegloticase Ab .